JPMorgan raised the firm’s price target on Medtronic (MDT) to $100 from $90 and keeps a Neutral rating on the shares ahead of the fiscal Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- 3 Best Dividend Aristocrat Stocks to Buy Now, 11/06/2025
- Medtronic Announces Executive Vice President’s Retirement
- Medtronic announces CMS finalizes coverage determination on renal denervation
- Medtronic’s Promising RDN Trial Results and Market Growth Potential Drive Buy Rating
- Medtronic’s Symplicity Spyral System: A Promising Growth Opportunity with Proven Efficacy